Lezing 'Gut microbiota in cancer cachexia : contribution to the disease and therapeutic prospects'

Voor wie
Studenten, Medewerkers, Alumni, Bedrijven
Wanneer
09-11-2018 van 11:30 tot 12:45
Waar
UGent-VIB-onderzoeksgebouw, Technologiepark 927, 9052 Zwijnaarde
Voertaal
Engels
Door wie
VIB-UGent Center for Inflammation Research (GE01/WE14/WE10)
Contact
ruth.vanlaere@ugent.be
Website
http://www.irc.ugent.be
Voeg toe aan mijn agenda

Laure Bindels, Louvain Drug Research Institute, UCL Gut microbtiota in cancer cachexia

Cancer cachexia is a complex multi-organ syndrome characterized by weight loss, muscle atrophy and fat mass loss. With a prevalence of 1 million people in Europe and only limited therapeutic options, there is a high medical need for new approaches to treat cachexia. In this context, we started a few years ago studying the therapeutic interest of modulating the gut microbiota in the context of cancer cachexia. We discovered that the gut microbiota composition and function as well as the gut function were deeply altered in cancer cachexia. Furthermore, our experimental results established that nutritional modulation of the gut microbiota using prebiotics and/or probiotics could constitute an interesting adjuvant therapeutic tool for cancer and associated cachexia.